Abbott Laboratories

New York Stock Exchange
Back to all articles
Somewhat Bullish +35

Ascentis Independent Advisors Boosts Holdings in Abbott Laboratories ...

AI-generated analysis

📈 Ascentis Independent Advisors raised its position in Abbott Laboratories by 132.4% in Q1, acquiring an additional 10,792 shares.

💰 The fund's total holding is now valued at $1,945,000 according to the latest SEC Form 13F filing.

📊 Abbott Laboratories reported Q1 EPS of $1.15, beating analyst estimates by $0.01.

💵 Revenue reached $11.16 billion, marking a 7.8% increase compared to the same quarter last year.

🏦 Institutional ownership stands at 75.18%, with several firms like Cornerstone Financial initiating new stakes.

👔 Director Daniel J. Starks purchased 10,000 shares for a total transaction value of $926,500.

💸 The company declared a quarterly dividend of $0.63 per share with an ex-dividend date of July 15th.

📉 JPMorgan Chase reduced its price target from $123.00 to $110.00 while maintaining an 'overweight' rating.

📉 Bank of America cut its price target from $120.00 to $102.00 in a report dated June 12th.

🎯 The consensus analyst price target for the stock is currently set at $118.42 with an average 'Moderate Buy' rating.

Bullish Signals
  • Abbott Laboratories beat quarterly earnings expectations, reporting $1.15 EPS versus a consensus of $1.14.
  • Revenue grew by 7.8% year-over-year to reach $11.16 billion, demonstrating solid top-line growth.
  • The company maintains healthy profitability metrics with a net margin of 13.90% and a return on equity of 17.62%.
  • Major institutional investor Ascentis Independent Advisors significantly increased its stake by over 130% in Q1.
  • Director Daniel J. Starks executed a $926,500 buy order, signaling continued insider confidence in the stock.
Risk Factors
  • JPMorgan Chase reduced its price target from $123.00 to $110.00, indicating potential downside pressure.
  • Bank of America lowered its price target from $120.00 to $102.00, reflecting a more cautious outlook.
  • Benchmark Financial cut its price objective from $145.00 to $120.00 despite reaffirming a 'buy' rating.
Full Analysis
Ascentis Independent Advisors significantly increased its stake in Abbott Laboratories (NYSE:ABT) by 132.4% during the first quarter, adding 10,792 shares to a total holding of 18,945 shares valued at $1.945 million. Several other institutional investors, including Cornerstone Financial and MidAtlantic Capital, also established new positions in the fourth quarter, while insider trading data reveals Director Daniel J. Starks purchased 10,000 shares for $926,500 and CFO Philip P. Boudreau acquired an additional 2,200 shares. Abbott Laboratories reported strong quarterly financial results on April 16th, posting earnings per share (EPS) of $1.15 against a consensus estimate of $1.14. The company generated revenue of $11.16 billion, representing a 7.8% year-over-year increase, with net margins at 13.90% and a return on equity of 17.62%. Management has provided guidance for fiscal year 2026 EPS between $5.38 and $5.58, and Q2 2026 EPS between $1.25 and $1.31. The company announced a quarterly dividend of $0.63 per share payable on August 17th to shareholders of record on July 15th, resulting in an annualized yield of 2.6%. Analyst sentiment remains mixed with recent price target reductions from major firms like JPMorgan Chase and Bank of America, though the stock maintains a 'Moderate Buy' average rating with a consensus price target of $118.42.